X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DIVIS LABORATORIES - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DIVIS LABORATORIES LUPIN LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 16.8 18.3 92.1% View Chart
P/BV x 3.9 4.0 99.1% View Chart
Dividend Yield % 0.8 1.6 50.2%  

Financials

 LUPIN LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
DIVIS LABORATORIES
Mar-16
LUPIN LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,1272,484 85.6%   
Low Rs1,294918 141.0%   
Sales per share (Unadj.) Rs304.1142.3 213.8%  
Earnings per share (Unadj.) Rs50.441.9 120.3%  
Cash flow per share (Unadj.) Rs60.746.3 131.0%  
Dividends per share (Unadj.) Rs7.5010.00 75.0%  
Dividend yield (eoy) %0.40.6 74.6%  
Book value per share (Unadj.) Rs243.8161.5 150.9%  
Shares outstanding (eoy) m450.58265.47 169.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.612.0 47.0%   
Avg P/E ratio x33.940.6 83.6%  
P/CF ratio (eoy) x28.236.7 76.8%  
Price / Book Value ratio x7.010.5 66.6%  
Dividend payout %14.923.9 62.3%   
Avg Mkt Cap Rs m770,740451,525 170.7%   
No. of employees `00016.43.7 441.0%   
Total wages/salary Rs m21,0773,649 577.6%   
Avg. sales/employee Rs Th8,379.610,184.4 82.3%   
Avg. wages/employee Rs Th1,289.0984.1 131.0%   
Avg. net profit/employee Rs Th1,388.72,998.5 46.3%   
INCOME DATA
Net Sales Rs m137,01637,764 362.8%  
Other income Rs m1,877848 221.2%   
Total revenues Rs m138,89338,612 359.7%   
Gross profit Rs m37,53514,138 265.5%  
Depreciation Rs m4,6351,182 392.2%   
Interest Rs m44623 1,923.3%   
Profit before tax Rs m34,33013,781 249.1%   
Minority Interest Rs m-880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m11,5362,662 433.3%   
Profit after tax Rs m22,70711,119 204.2%  
Gross profit margin %27.437.4 73.2%  
Effective tax rate %33.619.3 173.9%   
Net profit margin %16.629.4 56.3%  
BALANCE SHEET DATA
Current assets Rs m97,79030,947 316.0%   
Current liabilities Rs m53,8725,195 1,037.0%   
Net working cap to sales %32.168.2 47.0%  
Current ratio x1.86.0 30.5%  
Inventory Days Days85117 72.5%  
Debtors Days Days12185 142.4%  
Net fixed assets Rs m86,37917,027 507.3%   
Share capital Rs m901531 169.7%   
"Free" reserves Rs m105,73542,341 249.7%   
Net worth Rs m109,84442,877 256.2%   
Long term debt Rs m53,7395 1,143,383.0%   
Total assets Rs m224,37849,684 451.6%  
Interest coverage x77.9595.0 13.1%   
Debt to equity ratio x0.50 446,314.5%  
Sales to assets ratio x0.60.8 80.3%   
Return on assets %10.322.4 46.0%  
Return on equity %20.725.9 79.7%  
Return on capital %21.232.2 65.9%  
Exports to sales %49.185.3 57.6%   
Imports to sales %7.422.9 32.5%   
Exports (fob) Rs m67,24432,198 208.8%   
Imports (cif) Rs m10,1998,654 117.9%   
Fx inflow Rs m71,40532,270 221.3%   
Fx outflow Rs m17,8078,775 202.9%   
Net fx Rs m53,59823,496 228.1%   
CASH FLOW
From Operations Rs m-3,69010,379 -35.5%  
From Investments Rs m-69,434-4,135 1,679.3%  
From Financial Activity Rs m58,126-6,241 -931.3%  
Net Cashflow Rs m-14,9983 -454,484.8%  

Share Holding

Indian Promoters % 46.6 52.0 89.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 31.9 19.0 167.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.2 58.7%  
Shareholders   98,259 31,796 309.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare LUPIN LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 23, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - PANACEA BIOTECH COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS